This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Five Alzheimer’s disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin


Hamuro, Atsushi, Saito, Satona


Psychogeriatrics: The Official Journal Of The Japanese Psychogeriatric Society, Volume: 10, No.: 4, Pages.: 198-200

Year of Publication



The aim of the present study was to determine the efficacy, side-effects and tolerability of blonanserin for treating refractory behavioural psychological symptoms of dementia (BPSD). The present study was a 12-week, prospective, structured clinical trial of blonanserin for the treatment of BPSD. The degree of cognitive function, activities of daily living score, and the degree of BPSD were determined using the Mini-Mental State Examination (MMSE), Disability Assessment for Dementia (DAD), Neuropsychiatric Inventory (NPI) and the Rating Scale for Aggressive Behaviour in the Elderly (RAGE). The severity of extrapyramidal symptoms was assessed using the Drug-Induced Extrapyramidal Symptoms scale (DIEEPS). Five patients were enrolled. These patients met the NINCDS-ADRDA criteria. The patients were prescribed more than two kinds of existing antipsychotic drugs and were considered refractory cases; the drugs were discontinued because they were ineffectual and side-effects appeared. Each drug was prescribed independently for at least 2 weeks. The mean changes (at baseline and at the last week, respectively) in the MMSE (12.25, 9.25), in the DAD (6.5, 6.75), in the RAGE (5.5, 5.3) and in the DIEEPS (0.5, 1.5) were minimal. The mean changes in the NPI were two or fewer points. Some side-effects (one gait abnormality and one pneumonia) were observed. The results of this preliminary study show that blonanserin does not have adequate efficacy for the treatment of refractory BPSD.; © 2010 The Authors. Psychogeriatrics © 2010 Japanese Psychogeriatric Society.

Bibtex Citation

@article{HAMURO_2010, doi = {10.1111/j.1479-8301.2010.00338.x}, url = {}, year = 2010, month = {dec}, publisher = {Wiley-Blackwell}, volume = {10}, number = {4}, pages = {198--200}, author = {Atsushi HAMURO and Satona SAITO}, title = {Five Alzheimer{textquotesingle}s disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin}, journal = {Psychogeriatrics} }


adverse effects, aged, aged, 80 and over, aggression, alzheimer disease, basal ganglia diseases, blonanserin, chemically induced, diagnosis, dopamine d2 receptor antagonists, drug administration schedule, drug effects, drug resistance, drug therapy, female, humans, japan, male, mental disorders, mental status schedule, neuropsychological tests, piperazines, piperidines, prospective studies, psychology, psychometrics, statistics & numerical data, therapeutic use, treatment outcome

Countries of Study


Types of Dementia

Dementia (general / unspecified)

Types of Study

Before and After Study

Type of Outcomes

ADLs/IADLs, Behaviour, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions